Convert Pharmaceuticals is Drug Discovery in Belgium that focus on hypoxia-activated drug business. Founded in 2017. They cover business area such as developer, augment resistance, conventional anti-cancer treatment, proprietary insight, environment, expertise, drug and biomarker development, effective and well-tolerate HAPs, physician, cancer-affect patient population.
2017
( 7 years old in 2024 )
Hypoxia-activated Drug
-
Clos Chanmurly 13
4000 Liege
Belgium
Private
developeraugment resistanceconventional anti-cancer treatmentproprietary insightenvironmentexpertisedrug and biomarker developmenteffective and well-tolerate HAPsphysiciancancer-affect patient population
* We use standard office opening hours in near Convert Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Convert Pharmaceuticals is Drug Discovery business from Belgium that founded in 2017 (7 years old in 2024), Convert Pharmaceuticals business is focusing on Hypoxia-activated Drug.
Convert Pharmaceuticals headquarter office and corporate office address is located in Clos Chanmurly 13 4000 Liege Belgium.
Convert Pharmaceuticals was founded in Belgium.
In 2024, Convert Pharmaceuticals is currently focus on hypoxia-activated drug sector.
Above is snippet of Google Trends for "hypoxia-activated drug" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Convert Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
